An EU biotech looks to rewrite the ugly history of phosphatases, and it's taking $24M in funding to get off the ground
Long a lame duck in drug development, phosphatase enzymes are gaining some renewed interest after the success of a suite of Big Pharmas in hitting targets previously thought undruggable. Now, an EU biotech with some serious scientific backers is looking to bust the doors on phosphatases wide open.
Leaning on scientific know-how from two “Mr. Phosphatases” in the EU and US, Dutch biotech Anavo Therapeutics launched Thursday with $24 million in seed funding and the mission to develop modulators to rewrite the enzyme class’ ugly history of failure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.